Guardant Health
360Dx Top 30 Ticks up 2 Percent in August
Of the 30 companies in the index, 17 saw their share price increase, 12 saw their stock price decline, and one remained flat month over month.
Guardant Health Liquid Biopsy CDx Gets Japanese Regulatory Approval for Janssen Lung Cancer Drug
Patients with inoperable or recurrent NSCLC and EGFR exon 20 insertion mutations may be eligible for Janssen Pharmaceutical's amivantamab-vmjw.
Guardant Health Q2 Revenues Grow 29 Percent; Firm Raises Full-Year Guidance
Guardant reached a major milestone in Q2 with the FDA approval of its Guardant Shield liquid biopsy colon cancer screening test.
Guardant Health's Shield Test Approved by FDA as Primary Blood-Based CRC Screening Option
The FDA followed the majority opinion of a previously convened advisory committee in approving the assay with cautions in its label regarding test limitations.
Top Five Articles on 360Dx Last Week: Roche Gets EUA, Inks Licensing Deal; FDA Clearances; More
Last week, readers were most interested in a story about Roche's four-in-one molecular test receiving Emergency Use Authorization from the FDA.
Jun 14, 2024
Guardant Health Sues Tempus for Patent Infringement
Jun 4, 2024